Supplementary Data from Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case–Control Study Using the PLCO Cancer Screening Trial Data
Publication
, Other
In, H; Sarkar, S; Ward, J; Friedmann, P; Parides, M; Yang, J; Epplein, M
November 26, 2025
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
In, H., Sarkar, S., Ward, J., Friedmann, P., Parides, M., Yang, J., & Epplein, M. (2025). Supplementary Data from Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case–Control Study Using the PLCO Cancer Screening Trial Data. https://doi.org/10.1158/1055-9965.30721430
In, Haejin, Srawani Sarkar, Jessica Ward, Patricia Friedmann, Michael Parides, Julie Yang, and Meira Epplein. “Supplementary Data from Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case–Control Study Using the PLCO Cancer Screening Trial Data,” November 26, 2025. https://doi.org/10.1158/1055-9965.30721430.
In H, Sarkar S, Ward J, Friedmann P, Parides M, Yang J, et al. Supplementary Data from Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case–Control Study Using the PLCO Cancer Screening Trial Data. 2025.
In, Haejin, et al. Supplementary Data from Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case–Control Study Using the PLCO Cancer Screening Trial Data. 26 Nov. 2025. Crossref, doi:10.1158/1055-9965.30721430.
In H, Sarkar S, Ward J, Friedmann P, Parides M, Yang J, Epplein M. Supplementary Data from Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case–Control Study Using the PLCO Cancer Screening Trial Data. 2025.